Clinical trials: Enlarged Prostate (BPH)
Lower Urinary Tract Symptoms
UK ROPE Register Study
This registry study enables us to collect data on the treatment of LUTS using prostate artery embolisation (PAE), and other surgical methods to answer the following questions posed by NICE in 2013: Is PAE a safe and effective…
- Trial name
- UK ROPE (NCT02434575)
- Where
- 17 sites in United Kingdom
- Volunteers
- 318 people
- Sponsor
- Cardiff and Vale University Health Board
Enlarged Prostate
3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization
The purpose of this research study is to learn about how cone-beam Computerized Tomography scans (X-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries…
- Trial name
- NCT03164629
- Testing
- cone-beam CT 3D Emboguide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE)
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
The injection of botulinum neurotoxin A into the prostate represents an alternative, minimal invasive treatment in patient with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH).
- Trial name
- NCT01566292
- Testing
- BOTOX
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Catholic University of the Sacred Heart
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi
Overactive Bladder Syndrome, Bladder Outlet Obstruction
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Urodynamic examination evaluates storage and empting phases of the urinary bladder. It enables the clinician to correlate physiologic findings to patients' complains.
- Conditions
- Overactive Bladder Syndrome, Bladder Outlet Obstruction, Benign Prostate Enlargement, Stress Incontinence (Female) (Male)
- Trial name
- NCT03486639
- Testing
- IPSS questionnaire
- Where
- Israel
- Volunteers
- 330 people
- Sponsor
- Assaf-Harofeh Medical Center
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation
Benign Prostatic Hyperplasia
Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate
Many options currently exist to relieve the symptoms caused by benign prostatic hyperplasia (BPH). At present, transurethral resection of the prostate (TURP) serves as the surgical standard to which all other operative treatments…
- Trial name
- NCT00169767
- Testing
- Comparison study between KTP and HoLAP for BPH
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Indiana Kidney Stone Institute
Benign Prostatic Hyperplasia (BPH)
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00945490
- Testing
- NX-1207
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline
BPH With Large Prostate
Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate
The goal of this study is to compare the perioperative and postoperative characters of plasmakinetic enucleation of the prostate(PkEP) with bipolar TURP(B-TURP) for BPH patients with large prostate.
- Trial name
- NCT01637701
- Testing
- PkEP, B-TURP
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fuzhou General Hospital
Benign Prostate Hyperplasia
Plasmakinetic Enucleation of the Prostate and Open Prostatectomy to Treat Large Prostates
The investigators hypothesize that Plasmakinetic Enucleation of the Prostate (PkEP) might yield functional results comparable to OP but with lower perioperative morbidity, and have equivalent long-term efficacy with OP for large…
- Trial name
- NCT01952912
- Testing
- PkEP, OP
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fuzhou General Hospital
Prostatic Hyperplasia
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged…
- Trial name
- NCT01390870
- Testing
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy.
- Trial name
- NCT01332435
- Testing
- 5ARI + AB
- Volunteers
- 6,896 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Selective Median Lobe Surgery Outcomes Study
This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction.
- Conditions
- Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH), Benign Prostatic Obstruction, Urinary Retention
- Trial name
- UNVEIL-BPO (NCT07699718)
- Testing
- Selective Median Lobe TURP, Selective Median Lobe HoLEP/AEEP
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 420 people
- Sponsor
- Necmettin Erbakan University
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate
Many consider laser enucleation of the prostate the new 'gold standard' for the surgical treatment of benign prostatic hyperplasia (BPH) due to its excellent outcomes, high success rates, and long-term efficacy.
- Trial name
- NCT07187180
- Testing
- holmium laser, pulsed thulium laser
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Smita De
Prostate Hyperplasia
Implanted Nitinol Device (iTind) System in Chinese Males With Lower Urinary Tract Symptom Secondary to BPH
This is a prospective series of consecutive cases of patients undergoing iTind for the treatment of male LUTS.
- Trial name
- NCT05440981
- Testing
- iTind device
- Where
- Hong Kong
- Volunteers
- 13 people
- Sponsor
- Chinese University of Hong Kong
Benign Prostate Enlargement, Benign Prostate Hypertrophy(BPH)
Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:
Objectives of the study The aim of the study is to investigate and compare the treatment efficacy and safety of Oxiblume:CoQ10 (Ralivia) therapy vs placebo for BPH patients Study center The study will be coordinated by the…
- Conditions
- Benign Prostate Enlargement, Benign Prostate Hypertrophy(BPH), Benign Prostate Obstruction (BPO)
- Trial name
- NCT07638865
- Testing
- Oxiblume:CoQ10 (Ralivia) therapy
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- G.Gennimatas General Hospital